Digital medicine technologies, such as prescription digital therapeutics (DTx) for use as a companion therapy with high-value drugs, can help pharmaceutical companies improve efficacy and better treat patients with complex chronic conditions.

These technologies can enable as well as transform your business model, but to maximize their potential we need to understand and clearly assess the pros and cons, as well as define clear objectives, outcomes, and endpoints.

In this webinar we explore a decision framework to help choose the right digital medicine strategy for prescription DTx, add-on apps (OTC), and hybrids through pragmatic recommendations from leaders in the field including:

• Examples and use cases of digital medicine as both an enabler and a transformative capability
• Designing a business-first strategy and setting clear objectives
• Product lifecycle factors to consider including indications, market strategy, product strategy, etc.
• Involving all stakeholders in the product lifecycle from discovery through commercialization
• Insight into ways to compile clinical evidence for efficacy, safety, and cost-effectiveness

Speakers

Paul Upham
Head of Smart Devices, Roche / Genentech

Geoff MCCleary
Vice President, Global Connected Health Practice Leader Capgemini

Jaydev Thakkar
Chief Operating Officer Biofourmis

‍